Information Provided By:
Fly News Breaks for November 18, 2019
PODD
Nov 18, 2019 | 05:30 EDT
Piper Jaffray analyst Matt O'Brien took over coverage of Insulet and reiterates an Overweight rating on the shares with a price target of $200, up from $170. The company sells a "truly differentiated" insulin pump that has seen significant adoption among multiple daily injector diabetics, says the analyst.
News For PODD From the Last 2 Days
There are no results for your query PODD